Showing 3131-3140 of 5646 results for "".
- Clearside Biomedical Delivers Podium and Poster Presentations at ASRS Annual Meetinghttps://modernod.com/news/clearside-biomedical-delivers-podium-and-poster-presentations-at-asrs-annual-meeting/2480347/Clearside Biomedical announced that multiple presentations were given at the American Society of Retina Specialists (ASRS) Annual Meeting and at the OIS Retina Summit at ASRS, which took place October 7-12, 2021 in San Antonio, Texas. “The data pres
- AsclepiX Appoints Amir Shojaei, PhD, as Chief Scientific Officer and Executive Vice President, Clinical Developmenthttps://modernod.com/news/asclepix-appoints-dr-amir-shojaei-as-chief-scientific-officer-and-executive-vice-president-clinical-development/2480336/
- Ocuphire Announces Publications Featuring the Ref-1 Protein as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseaseshttps://modernod.com/news/ocuphire-announces-publications-featuring-the-ref-1-protein-as-a-novel-therapeutic-target-for-the-treatment-of-neovascular-retinal-diseases/2480333/
- Bausch + Lomb Announces Statistically Significant Topline Results from Second Phase 3 Trial of NOV03 for Dry Eye Diseasehttps://modernod.com/news/bausch-lomb-announces-statistically-significant-topline-results-from-second-phase-3-trial-of-nov03-for-dry-eye-disease/2480310/
- IrisVision Unveils Streamlined, Lightweight New Design for Award-Winning Low Vision Headsethttps://modernod.com/news/irisvision-unveils-streamlined-lightweight-new-design-for-award-winning-low-vision-headset/2480294/
- Aerie Pharmaceuticals Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEOhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-interim-executive-chair-and-departure-of-chairman-and-ceo/2480293/Aerie Pharmaceuticals announced that it is executing its succession plan and that effective September 17, 2021, Vicente Anido, PhD, no longer serves as the company’s Chairman and Chief Executive Officer or as a director of the company. Consistent with the succession plan in p
- Visus Unveils Additional Ophthalmic Drug Candidates for Corneal Wound Healing, Glaucoma and AMDhttps://modernod.com/news/visus-unveils-additional-ophthalmic-drug-candidates-for-corneal-wound-healing-glaucoma-and-amd/2480276/During its inaugural Capital Markets Day in New York City, Visus Therapeutics unveiled additional ophthalmic drug candidates with applications in development for corneal wound healing, glaucoma and age-related macular degeneration (AMD). Additionally, the company introduced a novel drug
- Luminopia One Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial for Amblyopiahttps://modernod.com/news/luminopia-one-demonstrates-safety-and-efficacy-in-phase-3-pivotal-trial/2480274/Luminopia announced the publication of positive phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia One. Published in Ophthalmology, the study was conducted at 21 academic and community sites in the U.S., in which childre
- Oxurion to Present Clinical and Preclinical Data at Upcoming Euretina 2021 Virtual Congresshttps://modernod.com/news/oxurion-to-present-clinical-and-preclinical-data-at-upcoming-euretina-2021-virtual-congress/2479493/Oxurion NV will be presenting preclinical and clinical data from its ongoing development programs, THR-149 and THR-687, as novel treatments for diabetic macular edema (DME) at the Euretina 2021 virtual congress. The upcoming annual meeting of the European Society of Retina Specialists is taking p
- AxeroVision Announces Phase 2 Results for Dry Eye Disease Creamhttps://modernod.com/news/axerovision-announces-phase-2-results-for-axr-270-for-treatment-of-dry-eye-disease-associated-with-mgd/2479478/AxeroVision announced positive results from a phase 2 investigational treatment of AXR-270, the company’s novel, proprietary, once-daily glucocorticoid cream, in patients with signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). I